Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Malignant Melanoma Clinical Trial

— ImmunoCobiVem  

Official title:

A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02902029
• Other study ID #: ImmunoCobiVem_2015
• Status: Completed
• Phase: Phase 2
• Start date: November 2016
• Est. completion date: March 2024

Study information

• Verified date: May 2024
• Source: University Hospital, Essen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Most patients with locally advanced or metastatic tumors succumb to their disease. Thus, there is a substantial need for novel therapeutic strategies to improve the outcome for patients with advanced or metastatic melanoma. Targeting the the Ras/Raf signalling pathway by BRAF and MEK inhibition as well as targeting immunologic checkpoint control with an antiPD-L1 antibody have emerged as treatment option.

In this study the best timing for sequential use of both treatment options (BRAF/MEK inhibition and antiPD-L1 antibody) in patients with unresectable or metastatic BRAFV600 mutant melanoma will be assessed.

Description:

At this time there is no experience concerning the sequencing strategy when using the two effective therapeutical approaches as targeting the Ras/Raf signalling pathway by BRAF and MEK inhibition or targeting immunologic checkpoint control with an antiPD-L1 antibody.

This is a prospective, open, multicenter, randomized phase II study in patients with unresectable or metastatic BRAFV600 mutant melanoma. In this study the scheduling of the treatment with a combined BRAF/MEK inhibition and the treatment with an anti-PD-L1 antibody will be assessed.

After a 3 months run-in period with vemurafenib and cobimetinib, all patients who did not show disease progression or treatment interruption for more than 28 days during run-in phase will be randomized in a 1:1 ratio:

• either to proceed vemurafenib and cobimetinib until disease progression and subsequently cross-over to atezolizumab treatment until disease progression (Arm A).

• or to receive the anti-PD-L1 antibody atezolizumab until disease progression and subsequently cross-back to vemurafenib and cobimetinib until disease progression (Arm B). In a translational research program tumor tissue, blood plasma and peripheral blood mononuclear cell will be analyzed to evaluate the biologic effects of treatment sequence on the molecular profile and biomarker expression in tissue and plasma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 186
• Est. completion date: March 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Be willing and able to provide written informed consent for the trial.

• Male or female patient being =18 years of age on day of signing informed consent.

• Histologically confirmed diagnosis of locally advanced, unresectable or metastatic melanoma AJCC (unresectable stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c) without active or untreated brain metastases; all known CNS lesions must have been treated with stereotactic therapy or surgery at least 4 weeks prior to the first dose of trial treatment AND the patient must be without evidence of clinical or radiographic disease progression in the CNS for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms must have returned to baseline, the patient must have no evidence of new or enlarging brain metastases, and the patient must not have used steroids for at least 3 weeks prior to trial treatment.

• No previous therapy for the advanced or metastatic stage. Prior adjuvant therapy is permitted (e.g. Interferon, Interleukin-2-therapy, chemo- or radiotherapy). Prior adjuvant therapy has to be terminated (last dose) at least 28 days before enrolment. Patients who are in follow-up period of a clinical trial in adjuvant setting and progressing may be enrolled / randomized.

• Measurable disease, i.e., present with at least one measurable lesion per RECIST, version 1.1, for the definition of a measureable lesion.

• Presence of BRAF mutation (V600) in tumor tissue.

• Performance status of 0 or 1 on the ECOG Performance Scale.

• Adequate organ function.

• Adequate cardiac function.

• Able to take oral medications.

• Female subject of childbearing potential should have a negative pregnancy test within 72 hours prior to receiving the first dose of study medication.

• Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use a highly effective form of contraception according to CTFG during the course of this study and for at least 6 months after completion of study therapy.

Exclusion Criteria:

• Use of any investigational or non-registered product within the 30 days before registration.

• Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study Day 1.

• Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).

• Prior therapy with a BRAF inhibitor (including but not limited to vemurafenib, dabrafenib, encorafenib and / or MEK inhibitor

• Prior major surgery.

• Known additional malignancy that is progressing or requires active treatment within 5 years prior to the study.

• Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

• History of leptomeningeal metastases.

• History or current evidence of central serous retinopathy (CSR) or retinal vein occlusion (RVO) or predisposing factors to RVO or CSR.

• History of retinal degenerative disease.

• History of allogenic bone marrow transplantation or organ transplantation.

• History of Gilbert's syndrome.

• Impaired cardiovascular function or clinically significant cardiovascular diseases.

• Uncontrolled arterial hypertension despite medical treatment.

• Impairment of gastrointestinal function or gastrointestinal disease.

• Evidence of interstitial lung disease or active, non-infectious pneumonitis.

• Active infection requiring systemic therapy.

• Positive test for Human Immunodeficiency Virus (HIV).

• Positive test for Hepatitis B or Hepatitis C.

• Known hypersensitivity reaction to any of the components of study treatment.

• Medical, psychiatric, cognitive or other conditions, including known alcohol or drug abuse.

• Patients having received a live, attenuated vaccine within 4 weeks prior to the first dose of trial treatment.

• Legal incapacity or limited legal capacity.

Related Conditions & MeSH terms

• Malignant Melanoma
• Melanoma

Intervention

Drug:
• Vemurafenib
960 mg vemurafenib BID until progression or unacceptable toxicity develops
• Cobimetinib
60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops
• Atezolizumab
1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops

Locations

Country	Name	City	State
France	Hôpital Ambroise-Paré	Boulogne-Billancourt
France	Hospital Claude Huriez	Lille
France	Hôpital de la Timone	Marseille
France	CHU de Nantes	Nantes
France	Centre Hospitalier Lyon Sud	Pierre-Bénite
Germany	Charité-Universitätsmedizin Berlin	Berlin
Germany	Elbe Kliniken Stade - Buxtehude	Buxtehude
Germany	Universitätsklinik Dresden	Dresden
Germany	HELIOS Klinikum Erfurt	Erfurt	Thuringia
Germany	University Hospital Essen, Department of Dermatology, Skin Cancer Center	Essen	North Rhine-Westphalia
Germany	Medizinische Hochschule Hannover	Hannover
Germany	National Centre for Tumour Diseases (NCT)	Heidelberg	BW
Germany	SLK-Kliniken Heilbronn GmbH	Heilbronn	Baden-Wuerttemberg
Germany	Universitätsklinikum des Saarlandes	Homburg/Saar
Germany	Universitäts-Hautklinik Kiel	Kiel
Germany	Universitätsklinikum Köln	Köln
Germany	Universitätsklinikum Leipzig	Leipzig
Germany	Universitätsklinikum Schleswig-Holstein	Lübeck
Germany	Gesellschaft für Klinische Forschung Ludwigshafen mbH	Ludwigshafen
Germany	Universitätsklinikum Mainz	Mainz
Germany	University Hospital Mannheim, Clinic for Dermatology	Mannheim	Baden-Wuerttemberg
Germany	Johannes Wesling Klinikum Minden	Minden
Germany	Klinikum der Universität München	München
Germany	Universitätsklinikum Tübingen	Tübingen
Germany	Uniklinikum Würzburg	Würzburg
Greece	"LAIKO" General Hospital of Athens	Athens
Serbia	Military Medical Academy	Belgrad

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Essen

Countries where clinical trial is conducted

France,  Germany,  Greece,  Serbia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to First Documented Disease Progression	Time to first documented disease progression (PFS1) defined as time from start of run-in phase (date of first intake of study drug) to first documented disease progression date according to RECIST v. 1.1. (PD1) or death by any cause, whichever occurs first.	4 years
Secondary	Time to Second Objective Disease Progression (PFS2)	Time to second objective disease progression (PFS2) defined as time from start of run-in phase (date of first intake of study drug) to second documented disease progression according to RECIST v. 1.1. (PD2) following randomization or death by any cause.	4 years
Secondary	Adverse events according to CTCAE Version 4.03 criteria (Safety / Toxicity)	All adverse events according to CTCAE Version 4.03 criteria, and all serious adverse events regardless of causal relationship to the administration of the investigational agents will be assessed	Until 90 days of discontinuation of dosing of the investigational product
Secondary	Overall survival	Overall Survival (OS) of a patient defined as the time from start of run-in phase (date of first intake of study drug) until documented date of death	4 years
Secondary	Overall survival 12 months	Overall survival rate at 12 months defined as the rate of patients alive 12 months after start of run-in phase (date of first intake of study drug)	1 year
Secondary	Overall survival 24 months	Overall survival rate at 24 months defined as the rate of patients alive 24 months after start of run-in phase (date of first intake of study drug)	2 years
Secondary	Overall survival 36 months	Overall survival rate at 36 months defined as the rate of patients alive 36 months after start of run-in phase (date of first intake of study drug)	3 years
Secondary	Overall survival 48 months	Overall survival rate at 48 months defined as the rate of patients alive 48 months after start of run-in phase (date of first intake of study drug)	4 years
Secondary	12-months disease control rate (DCR)	DCR is defined as the rate of patients showing complete response (CR) or partial response (PR) or stable disease (SD) at 12 months after start of run-in phase (date of first intake of study drug).	1 year
Secondary	24-months disease control rate (DCR).	DCR is defined as the rate of patients showing complete response (CR) or partial response (PR) or stable disease (SD) at 24 months after start of run-in phase (date of first intake of study drug).	2 years
Secondary	Rate of patients with progressive disease who could not cross-over to subsequent line of therapy due to deterioration of ECOG status or multiple and/or symptomatic brain metastases and/or leptomengial disease	From vemurafenib + cobimetinib to atezolizumab (Arm A); From atezolizumab to vemurafenib + cobimetinib (Arm B)	4 years
Secondary	Time from first documented tumor progression until second documented tumor progression	PFS3 definded as time from first documented tumor progression (PD1) until second documented tumor progression (PD2) after randomization or death by any cause, whichever occurs first.	4 years